
Pfizer Inc.
PFEHealthcare|Drug Manufacturers - General|US
$29.39
-0.06 (-0.20%)
DCF Value
$37.35
Graham Number
$15.77
Cash / Share
$2.50
Financials
Financial Snapshot
Market Cap
$167.51B
Enterprise Value
$228.36B
Revenue (TTM)
$63.62B
Net Income (TTM)
$4.03B
Cash & Investments
$14.27B
Net Cash
-$48.40B
Free Cash Flow (TTM)
$11.79B
Operating CF (TTM)
$14.17B
Debt/Equity
0.70
Cash Runway & Burn Rate
Company is cash-flow positive.
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $17.85B | $19.99B | $18.83B | $9.65B | $12.22B | $31.07B | $22.73B | $12.69B | $20.48B | $13.60B | $14.27B | |
| Operating Cash Flow | $15.90B | $16.47B | $15.83B | $12.59B | $14.40B | $32.58B | $29.27B | $8.70B | $12.74B | $11.71B | $14.17B | |
| Free Cash Flow | $13.90B | $14.25B | $13.63B | $9.99B | $11.61B | $29.87B | $26.03B | $4.79B | $9.84B | $9.08B | $11.79B | |
| Capital Expenditure | -$2.00B | -$2.22B | -$2.20B | -$2.59B | -$2.79B | -$2.71B | -$3.24B | -$3.91B | -$2.91B | -$2.63B | -$2.39B | |
| Financing Cash Flow | -$8.92B | -$13.04B | -$20.44B | -$8.48B | -$9.65B | -$9.82B | -$14.83B | $26.07B | -$17.14B | -$10.30B | -$8.43B |
R&D Spending
R&D (TTM)
$11.52B
R&D Intensity
18.1%
R&D Growth vs Prior
+10.4%
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $52.82B | $52.55B | $40.83B | $40.91B | $41.65B | $81.29B | $101.17B | $59.55B | $63.63B | $62.58B | $63.62B | |
| R&D Expense | $7.89B | $7.68B | $7.76B | $8.38B | $9.39B | $13.83B | $11.43B | $10.68B | $10.82B | $10.44B | $11.52B | |
| R&D % of Revenue | 14.9% | 14.6% | 19.0% | 20.5% | 22.6% | 17.0% | 11.3% | 17.9% | 17.0% | 16.7% | 18.1% | |
| SG&A | $14.84B | $14.80B | $12.61B | $12.73B | $11.60B | $12.70B | $13.68B | $14.77B | $14.73B | $13.79B | $13.81B |
Income Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $52.82B | $52.55B | $40.83B | $40.91B | $41.65B | $81.29B | $101.17B | $59.55B | $63.63B | $62.58B | $63.62B | |
| Cost of Revenue | $12.32B | $11.23B | $8.99B | $8.05B | $8.48B | $30.82B | $34.34B | $24.95B | $17.85B | $16.07B | $16.94B | |
| Gross Profit | $40.50B | $41.32B | $31.84B | $32.85B | $33.17B | $50.47B | $66.83B | $34.60B | $45.78B | $46.51B | $46.68B | |
| R&D | $7.89B | $7.68B | $7.76B | $8.38B | $9.39B | $13.83B | $11.43B | $10.68B | $10.82B | $10.44B | $11.52B | |
| SG&A | $14.84B | $14.80B | $12.61B | $12.73B | $11.60B | $12.70B | $13.68B | $14.77B | $14.73B | $13.79B | $13.81B | |
| Operating Income | $13.71B | $14.07B | $6.73B | $7.31B | $8.83B | $20.23B | $38.12B | $4.42B | $14.94B | $17.41B | $15.16B | |
| Interest Expense | $1.19B | $1.27B | $1.32B | $1.57B | $1.45B | $1.29B | $1.24B | $2.21B | $3.09B | $2.67B | $2.71B | |
| Pretax Income | $8.35B | $12.30B | $3.59B | $11.32B | $7.04B | $24.31B | $34.73B | $1.06B | $8.02B | $7.52B | $4.26B | |
| Net Income | $7.21B | $21.31B | $11.15B | $16.03B | $9.16B | $21.98B | $31.37B | $2.12B | $8.03B | $7.77B | $4.03B | |
| EPS (Diluted) | 1.17 | 3.52 | 1.87 | 2.87 | 1.63 | 3.88 | 5.47 | 0.37 | 1.41 | 1.36 | 0.70 | |
| EBITDA | $15.29B | $19.84B | $11.06B | $18.65B | $13.26B | $30.79B | $41.03B | $9.56B | $18.13B | $16.78B | $13.47B | |
| Shares Out. (M) | 6159.00 | 6058.00 | 5977.00 | 5675.00 | 5632.00 | 5708.00 | 5733.00 | 5709.00 | 5700.00 | 5686.00 | 5751.00 |
Balance Sheet
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $2.60B | $1.34B | $1.14B | $1.12B | $1.79B | $1.94B | $416.0M | $2.85B | $1.04B | $1.14B | $1.82B | |
| Short-Term Investments | $15.26B | $18.65B | $17.69B | $8.53B | $10.44B | $29.13B | $22.32B | $9.84B | $19.43B | $12.45B | $12.45B | |
| Total Current Assets | $38.95B | $41.14B | $49.93B | $32.80B | $35.07B | $59.69B | $51.26B | $43.33B | $50.36B | $42.90B | $45.01B | |
| Total Assets | $171.62B | $171.80B | $159.42B | $167.49B | $154.23B | $181.48B | $197.21B | $226.50B | $213.40B | $208.16B | $204.54B | |
| Total Current Liabilities | $31.11B | $30.43B | $31.86B | $37.30B | $25.92B | $42.67B | $42.14B | $47.79B | $42.99B | $36.98B | $31.73B | |
| Long-Term Debt | $30.40B | $32.67B | $32.91B | $34.65B | $35.57B | $34.76B | $31.93B | $60.50B | $57.41B | $61.64B | $60.00B | |
| Total Liabilities | $111.78B | $100.14B | $95.66B | $104.15B | $90.76B | $104.01B | $101.29B | $137.21B | $124.90B | $121.39B | $115.24B | |
| Stockholders' Equity | $59.54B | $71.31B | $63.41B | $63.14B | $63.24B | $77.20B | $95.66B | $89.01B | $88.20B | $86.48B | $89.00B | |
| Retained Earnings | $71.77B | $85.29B | $89.55B | $97.67B | $96.77B | $103.39B | $125.66B | $118.35B | $116.72B | $114.61B | $115.33B |
Cash Flow Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $15.90B | $16.47B | $15.83B | $12.59B | $14.40B | $32.58B | $29.27B | $8.70B | $12.74B | $11.71B | $14.17B | |
| Capital Expenditure | -$2.00B | -$2.22B | -$2.20B | -$2.59B | -$2.79B | -$2.71B | -$3.24B | -$3.91B | -$2.91B | -$2.63B | -$2.39B | |
| Free Cash Flow | $13.90B | $14.25B | $13.63B | $9.99B | $11.61B | $29.87B | $26.03B | $4.79B | $9.84B | $9.08B | $11.79B | |
| Investing Cash Flow | -$7.81B | -$4.74B | $4.53B | -$3.94B | -$4.27B | -$22.55B | -$15.78B | -$32.28B | $2.65B | -$1.35B | -$5.28B | |
| Financing Cash Flow | -$8.92B | -$13.04B | -$20.44B | -$8.48B | -$9.65B | -$9.82B | -$14.83B | $26.07B | -$17.14B | -$10.30B | -$8.43B | |
| Issuance of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Repurchase of Stock | -$5.00B | -$5.00B | -$12.20B | -$8.87B | $0.00 | $0.00 | -$2.00B | $0.00 | $0.00 | $0.00 | $0.00 | |
| Net Debt Issuance | $2.61B | -$941.0M | -$935.0M | $8.76B | -$12.76B | -$1.10B | -$3.52B | $35.95B | -$7.16B | -$74.0M | $1.75B | |
| Stock Based Comp. | $691.0M | $840.0M | $949.0M | $718.0M | $756.0M | $1.18B | $872.0M | $525.0M | $877.0M | $799.0M | $1.11B | |
| Net Change in Cash | -$1.05B | -$1.25B | -$206.0M | -$50.0M | $475.0M | $158.0M | -$1.51B | $2.45B | -$1.81B | $99.0M | $480.0M |
Dilution Tracker
Shares Outstanding
5700M
5-Year Share Growth
+1.0%
Stock Issuance (TTM)
$0.00
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 6159.00 | 6058.00 | 5977.00 | 5675.00 | 5632.00 | 5708.00 | 5733.00 | 5709.00 | 5700.00 | 5686.00 | 5751.00 | |
| Change vs Prior % | — | -1.6% | -1.3% | -5.1% | -0.8% | 1.3% | 0.4% | -0.4% | -0.2% | -0.2% | 1.1% | |
| Stock Issuance | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Repurchase | -$5.00B | -$5.00B | -$12.20B | -$8.87B | $0.00 | $0.00 | -$2.00B | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $691.0M | $840.0M | $949.0M | $718.0M | $756.0M | $1.18B | $872.0M | $525.0M | $877.0M | $799.0M | $1.11B |
Margins & Profitability
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 76.7% | 78.6% | 78.0% | 80.3% | 79.6% | 62.1% | 66.1% | 58.1% | 71.9% | 74.3% | 73.4% | |
| Operating Margin % | 26.0% | 26.8% | 16.5% | 17.9% | 21.2% | 24.9% | 37.7% | 7.4% | 23.5% | 27.8% | 23.8% | |
| Net Margin % | 13.7% | 40.6% | 27.3% | 39.2% | 22.0% | 27.0% | 31.0% | 3.6% | 12.6% | 12.4% | 6.3% | |
| EBITDA Margin % | 29.0% | 37.8% | 27.1% | 45.6% | 31.8% | 37.9% | 40.6% | 16.0% | 28.5% | 26.8% | 21.2% | |
| FCF Margin % | 26.3% | 27.1% | 33.4% | 24.4% | 27.9% | 36.7% | 25.7% | 8.0% | 15.5% | 14.5% | 18.5% | |
| ROE % | 12.1% | 29.9% | 17.6% | 25.4% | 14.5% | 28.5% | 32.8% | 2.4% | 9.1% | 9.0% | 4.6% | |
| ROA % | 4.2% | 12.4% | 7.0% | 9.6% | 5.9% | 12.1% | 15.9% | 0.9% | 3.8% | 3.7% | 2.0% | |
| ROIC % | 7.9% | 9.3% | 4.9% | 4.7% | 6.4% | 13.3% | 21.8% | 2.3% | 8.4% | 10.0% | 8.3% | |
| R&D / Revenue % | 14.9% | 14.6% | 19.0% | 20.5% | 22.6% | 17.0% | 11.3% | 17.9% | 17.0% | 16.7% | 18.1% |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 8.1% | -0.5% | -22.3% | 0.2% | 1.8% | 95.2% | 24.5% | -41.1% | 6.8% | -1.6% | |
| Gross Profit | 3.3% | 2.0% | -22.9% | 3.2% | 1.0% | 52.2% | 32.4% | -48.2% | 32.3% | 1.6% | |
| Operating Income | 5.7% | 2.6% | -52.2% | 8.6% | 20.8% | 129.2% | 88.4% | -88.4% | 238.2% | 16.5% | |
| Net Income | 3.7% | 195.3% | -47.7% | 43.7% | -42.8% | 140.0% | 42.7% | -93.2% | 279.0% | -3.2% | |
| EPS (Diluted) | 5.1% | 200.6% | -46.9% | 53.7% | -43.3% | 138.6% | 41.0% | -93.2% | 279.8% | -3.5% | |
| Operating Cash Flow | 9.6% | 3.6% | -3.9% | -20.5% | 14.4% | 126.2% | -10.2% | -70.3% | 46.5% | -8.2% | |
| Free Cash Flow | 6.8% | 2.5% | -4.4% | -26.7% | 16.2% | 157.2% | -12.8% | -81.6% | 105.2% | -7.7% | |
| R&D Expense | 2.6% | -2.6% | 1.0% | 8.1% | 12.0% | 47.2% | -17.4% | -6.6% | 1.3% | -3.6% | |
| SG&A Expense | 0.2% | -0.3% | -14.8% | 0.9% | -8.9% | 9.5% | 7.7% | 8.0% | -0.3% | -6.4% | |
| Total Assets | 2.5% | 0.1% | -7.2% | 5.1% | -7.9% | 17.7% | 8.7% | 14.9% | -5.8% | -2.5% | |
| Book Value / Share | -6.7% | 22.1% | -9.5% | 4.8% | 0.5% | 21.0% | 23.7% | -7.5% | -1.3% | -2.3% | |
| Debt | 5.6% | 3.8% | -2.0% | 21.8% | -24.7% | -3.3% | -5.8% | 103.2% | -5.4% | 0.6% | |
| Diluted Shares | -1.6% | -1.6% | -1.3% | -5.1% | -0.8% | 1.3% | 0.4% | -0.4% | -0.2% | -0.2% |
Valuation
P/E (TTM)41.58
10Y Low / Med / High9.16 / 18.68 / 76.67
P/S2.63
10Y Low / Med / High2.26 / 3.90 / 5.95
P/B1.88
10Y Low / Med / High1.64 / 3.15 / 4.28
EV/EBITDA16.96
10Y Low / Med / High7.84 / 13.76 / 25.64
EV/Revenue3.59
10Y Low / Med / High3.18 / 4.50 / 6.95
P/FCF14.21
10Y Low / Med / High11.04 / 15.59 / 33.90
Intrinsic Value Models (per share)
DCF Value
$37.35
Graham Number
$15.77
Cash / Share
$2.50
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio | 26.09 | 9.62 | 21.79 | 12.71 | 22.33 | 14.93 | 9.16 | 76.67 | 18.68 | 18.31 | 41.58 | |
| P/S Ratio | 3.55 | 3.90 | 5.95 | 5.06 | 4.91 | 4.07 | 2.84 | 2.73 | 2.36 | 2.26 | 2.63 | |
| P/B Ratio | 3.15 | 2.87 | 3.83 | 3.28 | 3.23 | 4.28 | 3.00 | 1.83 | 1.70 | 1.64 | 1.88 | |
| EV/EBITDA | 14.77 | 12.41 | 25.64 | 13.76 | 18.17 | 11.88 | 7.84 | 24.11 | 11.93 | 12.38 | 16.96 | |
| EV/Revenue | 4.28 | 4.69 | 6.95 | 6.27 | 5.79 | 4.50 | 3.18 | 3.87 | 3.40 | 3.32 | 3.59 |
Analyst Estimates & Quality
Altman Z-Score
2.16
Grey Zone
Piotroski F-Score
7
Strong
Forward Estimates (consensus)
| Metric | FY2026 | FY2027 | FY2028 |
|---|---|---|---|
| Revenue | $63.02B | $60.63B | $55.24B |
| Net Income | $17.35B | $16.74B | $14.43B |
| EPS | $3.03 | $2.94 | $2.48 |
| # Analysts (EPS) | 13 | 13 | 7 |
Dividends
Dividend/Share (TTM)
$1.72
Dividend Yield
5.85%
Frequency
Quarterly
Next Payment
Dec 7, 2026
Recent Payments
| Ex-Date | Pay Date | Amount | Frequency |
|---|---|---|---|
| Nov 6, 2026 | Dec 7, 2026 | $0.43 | Quarterly |
| Jul 24, 2026 | Sep 1, 2026 | $0.43 | Quarterly |
| May 8, 2026 | Jun 12, 2026 | $0.43 | Quarterly |
| Jan 23, 2026 | Mar 6, 2026 | $0.43 | Quarterly |
| Nov 7, 2025 | Dec 1, 2025 | $0.43 | Quarterly |
| Jul 25, 2025 | Sep 2, 2025 | $0.43 | Quarterly |
| May 9, 2025 | Jun 13, 2025 | $0.43 | Quarterly |
| Jan 24, 2025 | Mar 7, 2025 | $0.43 | Quarterly |
| Nov 8, 2024 | Dec 2, 2024 | $0.42 | Quarterly |
| Jul 26, 2024 | Sep 3, 2024 | $0.42 | Quarterly |
| May 9, 2024 | Jun 14, 2024 | $0.42 | Quarterly |
| Jan 25, 2024 | Mar 1, 2024 | $0.42 | Quarterly |
| Nov 9, 2023 | Dec 4, 2023 | $0.41 | Quarterly |
| Jul 27, 2023 | Sep 5, 2023 | $0.41 | Quarterly |
| May 11, 2023 | Jun 9, 2023 | $0.41 | Quarterly |
| Jan 26, 2023 | Mar 3, 2023 | $0.41 | Quarterly |
| Nov 3, 2022 | Dec 5, 2022 | $0.40 | Quarterly |
| Jul 28, 2022 | Sep 6, 2022 | $0.40 | Quarterly |
| May 12, 2022 | Jun 10, 2022 | $0.40 | Quarterly |
| Jan 27, 2022 | Mar 4, 2022 | $0.40 | Quarterly |
Revenue Segments
By Product
| Segment | 2019 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Biopharma Segment | $39.42B | $79.56B | $98.99B | $57.19B | $62.40B | $61.20B |
| Upjohn Segment | $10.23B | — | — | — | — | — |
| Business Innovation Segment | — | — | — | $1.31B | — | — |
| Segment Reporting, Reconciling Item, Corporate Nonsegment | — | — | — | — | — | $1.38B |
By Geography
| Segment | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Developed Europe | $7.79B | $18.34B | $21.98B | $11.65B | — | — |
| Developed Rest Of World | $4.04B | $12.51B | $15.78B | $7.76B | $16.06B | $16.19B |
| Emerging Markets | $8.37B | $20.70B | $20.10B | $12.00B | $8.88B | $9.31B |
| UNITED STATES | $21.71B | $29.75B | $42.47B | $27.09B | $38.69B | $37.08B |